DPI-386SS

DPI-386SS is a synthetic small molecule platform candidate developed by Defender Pharmaceuticals. It functions as a muscarinic acetylcholine receptor antagonist (anticholinergic) and is based on the chemical structure of scopolamine. The drug is designed for intranasal administration using Defender's proprietary delivery technology, which aims to provide rapid absorption and improved bioavailability compared to traditional delivery methods. While other candidates in the DPI-386 series are being developed for specific indications such as motion sickness and postoperative nausea, DPI-386SS is categorized as a non-indication-specific platform molecule currently in the preclinical stage of development.